A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse Clinical Trial

Official title: A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Status Active, not recruiting

Clinical Trial Summary

The aim of the current trial is to evaluate if combination treatment with venetoclax + ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (RR CLL) can lead to MRD negativity, which may induce long lasting remissions for MRD-negative patients randomized to stopping treatment after 15 induction cycles.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia in Relapse
• Chronic Lymphocytic Leukemia in Remission
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

• NCT number: NCT03226301
• Study type: Interventional
• Source: Stichting Hemato-Oncologie voor Volwassenen Nederland
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 23, 2017
• Completion date: June 21, 2026